Coronavirus disease 2019 and cardiovascular system: A narrative review

Felix Kwenandar; Karunia Valeriani Japar; Vika Damay; Timotius Ivan Hariyanto; Michael Tanaka; Nata Pratama Hardjo Lugito; Andree Kurniawan

doi:10.1016/j.ijcha.2020.100557

Coronavirus disease 2019 and cardiovascular system: A narrative review

Int J Cardiol Heart Vasc. 2020 Jun 3:29:100557. doi: 10.1016/j.ijcha.2020.100557. eCollection 2020 Aug.

Authors

Felix Kwenandar¹, Karunia Valeriani Japar¹, Vika Damay¹, Timotius Ivan Hariyanto¹, Michael Tanaka², Nata Pratama Hardjo Lugito³, Andree Kurniawan³

Affiliations

¹ Faculty of Medicine, Pelita Harapan University, Banten, Indonesia.
² Faculty of Medicine, Pelita Harapan University, Department of Cardiology, Siloam Hospital Lippo Village, Karawaci, Banten, Indonesia.
³ Faculty of Medicine, Pelita Harapan University, Department of Internal Medicine, Siloam Hospital Lippo Village, Karawaci, Banten, Indonesia.

Abstract

At the end of 2019, a viral pneumonia disease called coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), emerged in Wuhan, China. This novel disease rapidly spread at an alarming rate that as a result, it has now been declared pandemic by the World Health Organization. Although this infective disease is mostly characterized by respiratory tract symptoms, increasing numbers of evidence had shown considerable amounts of patients with cardiovascular involvements and these were associated with higher mortality among COVID-19 patients. Cardiac involvement as a possible late phenomenon of the viral respiratory infection is an issue that should be anticipated in patients with COVID-19. Cardiovascular manifestation in COVID-19 patients include myocardial injury (MI), arrhythmias, cardiac arrests, heart failure and coagulation abnormality, ranging from 7.2% up to 33%. The mechanism of cardiac involvement in COVID-19 patients involves direct injury to myocardial cells mediated by angiotensin-converting enzyme 2 (ACE2) receptors as suggested by some studies, while the other studies suggest that systemic inflammation causing indirect myocyte injury may also play a role. Combination of proper triage, close monitoring, and avoidance of some drugs that have cardiovascular toxicity are important in the management of cardiovascular system involvement in COVID-19 patients. The involvement of the cardiovascular system in COVID-19 patients is prevalent, variable, and debilitating. Therefore, it requires our attention and comprehensive management.

Keywords: ACE2; ACE2, Angiotensin Converting Enzyme-2; ARDS, Acute respiratory distress syndrome; CFR, Case-fatality rate; CK-MB, Creatine Kinase Myocardial Band; COVID-19; COVID-19, Coronavirus Disease 2019; CPVT, Catecholaminergic polymorphic ventricular tachycardia; CVD, Cardiovascular disease; Cardiovascular; Coronavirus; DIC, Disseminated intravascular coagulation; FDP, Fibrin degradation products; Hs-cTnI, High-sensitive cardiac troponin I; LV, Left Ventricle; MI, Myocardial Infarction; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PCI, Percutaneous coronary intervention; SARS-CoV-2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; TnT, Troponin T; VTE, Venous thromboembolism.

Publication types

Review